TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: DEPORRA-CoProst: Assessment of New Fluorescence Imagery Techniques Using Prostate Chips From Transurethral Resections

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male patient over 18 years old.~* Patient scheduled for trans-urethral resection of prostate with:~  1. prostate specific antigen (PSA) blood level ≤ 4 ng/ml and age \> 80 years old~ 2. a suspected prostate cancer after a digital rectal examination (DRE) and a PSA blood level \> 50 ng/ml or an existing prostate cancer~* Patient affiliated to social security or beneficiary of such a regime.~Exclusion Criteria:~* Protected patient referred to in Articles L1121-6 to L1121-8 of the Code of Public Health

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluorescence assesment (Type: EXPERIMENTAL): All patients undergo a transurethral resection.~There are four different steps in the study:~* the first step: fresh prostatic tissue of 30 subjects will be use to asses the fluorescence signal and the entire chain,~* the second step: fresh prostatic tissue of 10 subjects will be used to asses the immunolabelling protocol,~* the third step: fresh prostatic tissue of 20 subjects will be used to asses the use of the FEMTO-ST institute medical device,~* the four step: the fresh prostatic tissue from the 10 subjects of the second step will be evaluated to verify the preservation of morphological structure with the use of the Light-CT scanner.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven non-Hodgkin's disease that has failed both prior high-dose chemotherapy and bone marrow transplantation~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC greater than 2,000/mm\^3~* Platelet count greater than 20,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.5 mg/dL~Renal:~* Creatinine no greater than 2.5 mg/dL~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No serious active infections~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulatory agents (e.g., interferon or interleukin-2)~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~Endocrine therapy:~* At least 4 weeks since prior corticosteroids~* No concurrent corticosteroids~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered~Surgery:~* Not specified~Other:~* No prior antineoplaston therapy~* No other concurrent antineoplastic agents~* No concurrent antibiotics, antifungals, or antivirals

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antipsychotic Induced Structural and Functional Brain Changes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with diagnosis of schizophrenia according to DSM-5~* Age 18-65 years~* Written declaration of consent~* Subjects being contractually and mentally capable to attend the medical staffs' orders.~* MRI capability~Exclusion Criteria:~* Relevant somatic diseases, which could have an impact on the conduct of the study based on clinical judgement of the treating physician (e.g. epilepsy, cancer)~* Prior insufficiently documented drug therapy with antipsychotics~* Magnetic metals in and on the body, cardiac pacemakers and body piercings.~* Pregnancy or lactation~* Hospitalization of the patient ordered by the court or public authorities~* Relationship of dependence or employment to sponsor or investigator~* Simultaneous participation in another clinical trial (participation in an APIC subproject excluded)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Maintenance treatment (Control) (Type: ACTIVE_COMPARATOR): 287 female and male patients with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders-V (DSM-V) will be directed randomly to the maintenance treatment group (control). Patients will be treated according to the current clinical standard of long-term maintenance antipsychotic treatment. Study related procedures include safety assessments (physical examination, questionaires), laboratory assessments (blood sampling, urine analysis), efficacy assessments (questionaires) and volumetric Magnetic Resonance Imaging (structural MRI incl. volumetry). Study procedures are the same for both study groups (control/experimental).
- Intermittent Treatment (Experimental) (Type: EXPERIMENTAL): 287 female and male patients with schizophrenia according to DSM-V will be directed randomly to the intermittent treatment group (experimental). Patients directed to this group will be tapered off medication.~Study related procedures include safety assessments (physical examination, questionaires), laboratory assessments (blood sampling, urine analysis), efficacy assessments (questionaires) and volumetric Magnetic Resonance Imaging (structural MRI incl. volumetry). Study procedures are the same for both study groups (control/experimental).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria Participation in study EPO906A2120E1~* Age ≥ 18 years of age~* Life expectancy ≥ 3 months~* Histologically documented advanced solid tumors which have progressed after standard systemic therapy or for which standard systemic therapy does not exist~* Completed all PK sampling in the core study~Exclusion criteria~* Known diagnosis of human immunodeficiency virus (HIV) infection, hepatitis~* Female patients who are pregnant or breast feeding~* Patients with a severe and/or uncontrolled medical disease~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Informed Consent as documented by signature~2. Subjects (males and females) age ≥ 18 years~3. ECOG \< 3~4. Subjects with pyrexia grade 1\*- 4 and elevated CRP with persistent fever after one day of antipyretic therapy with or without at least one other additional symptom of cytokine release syndrome such as nausea, headache, tachycardia, hypotension, maculopapular rash, shortness of breath, transaminitis, renal failure, dehydration~5. Elevated CRP serum levels further than normal baseline levels (\> 3.0 mg/L)~6. Subjects with resected, non-resectable, adjuvant or metastatic BRAF+ melanoma treated with :~   * BRAF inhibitor (dabrafenib) in combination with MEK inhibitor (trametinib)~  * BRAF inhibitor (dabrafenib) in combination with MEK inhibitor (trametinib) preceded by therapy with anti-PD-1/PD-L1 and/or anti CTLA-4 inhibitor~  * BRAF inhibitor (dabrafenib) in combination with MEK inhibitor (trametinib) plus anti-PD- 1/PD-L1 inhibitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: OTHER): The patients will be administered Tocilizmab (Actemra) at the following dosage :~* First dose: 8mg/kg, max. 800mg iv. during 60min~* If necessary second dose: 8mg/kg, max. 800mg iv. during 60min after 20-36 hours from first dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lumbar Transforaminal Epidural Corticosteroid Injection(s) Versus Defined Physical Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patient inclusion highlights: L4-5 or L5-S1 HNP with leg\>back pain; duration \< 12 weeks.~1. Low back pain episode less than or equal to 12 weeks in duration, within the current pain episode. This may be the initial pain episode or the onset of a most recent episode of pain, preceded by at least a six month pain free interval.~2. Visual analog score (VAS) or screening Likert pain scale score three day average and present pain of at least four/ten at baseline.~3. Age 18 to 64.~4. Subjects will have focal disc herniation with unilateral radicular/neurological deficits or correlating radicular symptoms. These radicular symptoms/signs are defined as pain or paresthesias below the knee, pain reproduction with straight-leg-raising and/or extension or quadrant maneuvers, and radicular pattern sensory, reflex or strength changes. These symptoms will be consistent with their level of nerve root impingement and will primarily involve the L5 and/or S1 roots.~5. Those with canal and foraminal compromise due to disc herniation at L4-5 with L5 \> L4 signs and symptoms WILL be included.~Exclusion Criteria:~1. Litigation.~2. Workers compensation.~3. Those receiving remuneration for their pain, e.g. disability.~4. Back pain greater than leg pain.~5. Scoliosis of \> 15 degrees~6. Those unable to read English and complete the assessment instruments.~7. Spondylolysis, with or without spondylolithesis, degenerative spondylolithesis, or stenosis due primarily to degenerative bony or soft tissue changes.~8. Systemic inflammatory arthritis (e.g. rheumatoid, lupus).~9. Addictive behaviour, severe clinical depression, or psychotic features.~10. Significant lower extremity pathology that effects gait.~11. Sustained cervical or thoracic pain that is present at a level \>4/10 on VAS.~12. Possible pregnancy or other reason that precludes the use of fluoroscopy.~13. Prior lumbar surgery~14. Prior epidural steroid injections for treatment of current episode or within the prior year~15. Bilateral radicular signs/symptoms (\< 90% laterality of pain intensity or bilateral neurological signs)~16. No more than 4 PT sessions for current episode

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Lumbar Transforaminal Epidural Corticosteroid Injection (Type: OTHER): None
- Physical Therapy (Type: OTHER): None
- Cohort observational (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mitomycin C and Ifosfamide in Treating Patients With Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed adenocarcinoma of the pancreas~  * Stage IV disease~ * Metastatic disease~* Prior treatment with gemcitabine-based chemotherapy, also in the adjuvant setting, with progression-free survival at ≤ 12 months~* Measurable disease according RECIST criteria~* No symptomatic brain metastases~PATIENT CHARACTERISTICS:~* Karnofsky performance status 60-100% (80-100% in patients \> 70 years of age)~* Adequate bone marrow, liver, and kidney function~* Not pregnant or nursing~* No other prior or concurrent malignancies except surgically cured carcinoma in situ of the cervix, basal cell or squamous cell carcinoma of the skin, or other neoplasms with no evidence of disease ≥ 5 years~* No severe comorbidities that could compromise safety, including any of the following:~  * Cardiac failure~ * Cardiac arrhythmia~ * Prior myocardial infarction within the past 4 months~ * History of psychiatric disabilities~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior mitomycin C and ifosfamide~* No concurrent treatment with experimental drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures;~* Men and women 18 years and older;~* Group I PAH, defined as a mPAP≥25mmHg, PCWP\<15mmHg and PVR\[The PVR =(mPAP-PCWP)/CO\]\>3.0 Woods unit.~Exclusion Criteria:~General exclusion criteria:~* Pregnancy and breast feeding mother;~* Estimated life expectancy \<12 months;~* Scheduled major surgery in the next 6 months;~* Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk;~* Previous enrolment in this study or treatment with an investigational drug or device under another study protocol in the past 30 days.~Procedural exclusion criteria:~* WHO group II, III, IV, V PH~* Severe Renal dysfunction (Ccr\<30 ml/min)~* Blood platelet count\<100,000/L~* Expected life span\<6-month~* Systematical inflammation~* Malignant cancer(s)~* Tricuspid valve stenosis, Supra-pulmonary valve stenosis~* Allergic to studied drugs or metal materials.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PADN + sildenafil (Type: EXPERIMENTAL): Two to three ablations at 1-15 W for 120 seconds at each point were performed in the distal bifurcation area of the main PA.
- sham PADN + sildenafil (Type: SHAM_COMPARATOR): The radiofrequency ablation catheter placed, no ablations.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Participants With Chronic Kidney Disease.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* chronic kidney disease, stage 3 or 4;~* anemia (baseline hemoglobin between 9 and 11 grams per deciliter \[g/dL\]).~Exclusion Criteria:~* previous therapy with ESA within 12 weeks prior to screening;~* significant acute or chronic bleeding such as overt gastrointestinal bleeding;~* red blood cell transfusions within 8 weeks before screening;~* active malignant disease (except non-melanoma skin cancer).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methoxy Polyethylene Glycol-epoetin Beta (Type: EXPERIMENTAL): Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 micrograms per kilogram (mcg/kg) body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Key inclusion Criteria:~* Diagnosis of relapsing form of MS~* Have declared a desire/plan to discontinue treatment with Tecfidera due to tolerability issues and/or lack of efficacy~* Expanded Disability Status Scale (EDSS) score 0 to 5.0 inclusive~* Other protocol defined inclusion criteria could apply~Key exclusion Criteria:~* Pregnant or lactating~* Significant renal or hepatic impairment or other significant disease that would compromise adherence and completion of the trial~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Rebif® via Rebidose® auto-injector (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Awake Surgery With Electrocorticographic Recordings in the Management of Gliomas and Correlation With Imaging Data (ECoG)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Man or woman over 18 years-old~* Subject with a non-recurrent glial lesion requiring surgery in vigilant condition;~* Brain lesion located in the functional zone;~* Major not protected within the meaning of the law;~* Subject affiliated to a Health Insurance scheme;~* No medical contraindication to performing an MRI (pacemaker);~* No medical contraindication to surgery and anesthesia;~* Karnofski index\> 70;~* Subject having signed an informed consent.~Exclusion Criteria:~* Minor subject, pregnant or breastfeeding woman;~* Major subject subject under measure of legal protection, guardianship or deprived of liberty by judicial or administrative decision;~* Subject hospitalized without consent;~* Subject treated with antipsychotics (neuroleptic or lithium);~* Subject who has already been treated for his glial lesion by surgery and / or radiotherapy;~* Subject refusing to sign an informed consent.~* Subject wishing to discontinue participation in the study before completion;~* Subject for which the surgical intervention and / or the ECoG recording could not be carried out after admission to the operating room (whatever the reason).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subject with a non-recurrent glial lesion requiring surgery in vigilance (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recipient of a first (primary) live or deceased (after brain or cardiac death) donor liver transplant~* Willing and able to provide written informed consent~* Male or Female, age 18-70 years old~* Medical MELD score ≤30 at time of transplant (calculated based on serum bilirubin, creatinine and INR, i.e. not taking exception points into account)~* Quantifiable HCV RNA at time of listing or transplant evaluation~* HCV genotype 1a or 1b infection~* Female patients must have a negative pregnancy test at enrolment~Exclusion Criteria:~* Liver re-transplantation~* Recipients of multiple solid organ transplants~* Estimated GFR \<30ml/min at time of transplant~* Participants transplanted for fulminant hepatic failure~* Participants co-infected with HBV or HIV~* Previous treatment with a Sofosbuvir or Ledipasvir containing regimen~* Participation in an interventional clinical trial within 1 month prior to enrolment~* Known allergies or hypersensitivity to Sofosbuvir or Ledipasvir~* Pregnancy and/or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SOF and LDV (Type: EXPERIMENTAL): Single arm: All participants will be started on Sofosbuvir (SOF) 400 mg and Ledipasvir (LDV) 90 mg as a fixed dose combination (FDC) tablet p.o. once daily with or without food starting at the time of liver transplantation (OLT), i.e. first doses given immediately prior to OLT, and continuing for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues